Literature DB >> 17965932

Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies.

Joao P Lopes1, Catarina R Oliveira, Paula Agostinho.   

Abstract

Tau hyperphosphorylation, amyloid plaques, and neuronal death are major neuropathological features of Alzheimer's disease (AD) and Prion-related encephalopathies (PRE). Cyclin-dependent kinase 5 (Cdk5) is a serine/threonine kinase, active in post-mitotic neurons, where it regulates survival and death pathways. Overactivation of Cdk5 is conferred by p25, a truncated fragment of the p35 activator formed upon calpain activation. Cdk5 deregulation causes abnormal phosphorylation of microtubule-associated protein tau, leading to neurodegeneration. In this work we investigated the involvement of Cdk5 in the neurodegeneration triggered by amyloid-beta (Abeta) and prion (PrP) peptides, the culprit agents of AD and PRE. As a work model, we used cultured rat cortical neurons treated with Abeta 1-40 and PrP 106-126 synthetic peptides. The obtained data show that apoptotic neuronal death caused by both the peptides was in part due to Cdk5 deregulation. After peptide treatment, p25 levels were significantly enhanced in a pattern consistent with the augment in calpain activity. Moreover, Abeta 1-40 and PrP 106-126 increased the levels of tau protein phosphorylated at Ser202/Thr205. Cdk5 (roscovitine) and calpain (MDL28170) inhibitors reverted tau hyperphosphorylation and prevented neuronal death caused by Abeta 1-40 and PrP 106-126. This study demonstrates, for the first time, that Cdk5 is involved in PrP-neurotoxicity. Altogether, our data suggests that Cdk5 plays an active role in the pathogenesis of AD and PRE.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17965932     DOI: 10.1007/s10571-007-9224-3

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  44 in total

Review 1.  Cycling at the interface between neurodevelopment and neurodegeneration.

Authors:  M D Nguyen; W E Mushynski; J-P Julien
Journal:  Cell Death Differ       Date:  2002-12       Impact factor: 15.828

2.  Comparative study of microglia activation induced by amyloid-beta and prion peptides: role in neurodegeneration.

Authors:  Pedro Garção; Catarina R Oliveira; Paula Agostinho
Journal:  J Neurosci Res       Date:  2006-07       Impact factor: 4.164

3.  Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta.

Authors:  Tong Li; Cheryl Hawkes; Hamid Y Qureshi; Satyabrata Kar; Hemant K Paudel
Journal:  Biochemistry       Date:  2006-03-14       Impact factor: 3.162

4.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

Authors:  I Grundke-Iqbal; K Iqbal; Y C Tung; M Quinlan; H M Wisniewski; L I Binder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

5.  Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias.

Authors:  M Riemenschneider; S Wagenpfeil; H Vanderstichele; M Otto; J Wiltfang; H Kretzschmar; E Vanmechelen; H Förstl; A Kurz
Journal:  Mol Psychiatry       Date:  2003-03       Impact factor: 15.992

Review 6.  A decade of CDK5.

Authors:  R Dhavan; L H Tsai
Journal:  Nat Rev Mol Cell Biol       Date:  2001-10       Impact factor: 94.444

7.  A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains.

Authors:  Huang Chun Tseng; Ying Zhou; Yong Shen; Li Huei Tsai
Journal:  FEBS Lett       Date:  2002-07-17       Impact factor: 4.124

8.  Hyperphosphorylated tau deposition parallels prion protein burden in a case of Gerstmann-Sträussler-Scheinker syndrome P102L mutation complicated with dementia.

Authors:  Keisuke Ishizawa; Takashi Komori; Tomokazu Shimazu; Toshimasa Yamamoto; Tetsuyuki Kitamoto; Kunio Shimazu; Takanori Hirose
Journal:  Acta Neuropathol       Date:  2002-05-14       Impact factor: 17.088

9.  Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function.

Authors:  M Ankarcrona; J M Dypbukt; E Bonfoco; B Zhivotovsky; S Orrenius; S A Lipton; P Nicotera
Journal:  Neuron       Date:  1995-10       Impact factor: 17.173

10.  Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.

Authors:  Jonathan C Cruz; Huang-Chun Tseng; Joseph A Goldman; Heather Shih; Li-Huei Tsai
Journal:  Neuron       Date:  2003-10-30       Impact factor: 17.173

View more
  26 in total

1.  Effect of GAPT extract on expression of tau protein and its phosphorylation related enzymes in hippocampal neurons of APPV717I transgenic mice.

Authors:  Jing-Nian Ni; Jing Shi; Xue-Kai Zhang; Yi-Chang Yang; Xiao-Meng Liu; Ming-Qing Wei; Ting Li; Peng-Wen Wang; Jin-Zhou Tian; Yong-Yan Wang
Journal:  Chin J Integr Med       Date:  2017-06-20       Impact factor: 1.978

2.  Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer's disease.

Authors:  M Cuadrado-Tejedor; I Hervias; A Ricobaraza; E Puerta; J M Pérez-Roldán; C García-Barroso; R Franco; N Aguirre; A García-Osta
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

3.  p35 and Rac1 underlie the neuroprotection and cognitive improvement induced by CDK5 silencing.

Authors:  Rafael Andres Posada-Duque; Alejandro López-Tobón; Diego Piedrahita; Christian González-Billault; Gloria Patricia Cardona-Gomez
Journal:  J Neurochem       Date:  2015-05-04       Impact factor: 5.372

4.  Sustained (S)-roscovitine delivery promotes neuroprotection associated with functional recovery and decrease in brain edema in a randomized blind focal cerebral ischemia study.

Authors:  Estelle Rousselet; Anne Létondor; Bénédicte Menn; Yann Courbebaisse; Marie-Lise Quillé; Serge Timsit
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-01       Impact factor: 6.200

Review 5.  Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease.

Authors:  Erik C Gunther; Stephen M Strittmatter
Journal:  J Mol Med (Berl)       Date:  2009-12-04       Impact factor: 4.599

6.  Changes of tau profiles in brains of the hamsters infected with scrapie strains 263 K or 139 A possibly associated with the alteration of phosphate kinases.

Authors:  Gui-Rong Wang; Song Shi; Chen Gao; Bao-Yun Zhang; Chan Tian; Chen-Fang Dong; Rui-Min Zhou; Xiao-Li Li; Cao Chen; Jun Han; Xiao-Ping Dong
Journal:  BMC Infect Dis       Date:  2010-04-01       Impact factor: 3.090

7.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

Review 8.  Tau-based treatment strategies in neurodegenerative diseases.

Authors:  Anja Schneider; Eckhard Mandelkow
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

Review 9.  Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration.

Authors:  P S Vosler; C S Brennan; J Chen
Journal:  Mol Neurobiol       Date:  2008-08-07       Impact factor: 5.590

10.  COL25A1 triggers and promotes Alzheimer's disease-like pathology in vivo.

Authors:  Ying Tong; Ying Xu; Kimberly Scearce-Levie; Louis J Ptácek; Ying-Hui Fu
Journal:  Neurogenetics       Date:  2009-06-23       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.